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treatment related mortality (TRM) has been reported.
We report consecutive 10 patients with relapsed and re-
fractory MM undergoing allo-SCT in Japanese Red Cross
Medical Center between 2009 and 2014. Median age at
transplantation was 50.5 (31-60). Number of previous ASCT
was one in 5 patients and two in the others. Conditioning
regimen consisted of ﬂudarabine (Flu; 125mg/m2),
melphalan (Mel; 140mg/m2), and total body irradiation
(TBI; 0Gy:1, 2Gy:1, 4Gy: 1, 8Gy:7). Tacrolimus or cyclo-
sporine with or without short term MTX was used as GVHD
prophylaxis. Three out of ten patients received matched
related peripheral blood stem cells and the others received
unrelated stem cells (unrelated bone marrow: 5, cord blood:
2). Two years progression free survival (PFS) and OS were
39.4% and 57.9%, respectively. Interestingly, among patients
transplanted from unrelated donors, two years PFS and OS
were 41.7% and 80%, respectively. In this analysis, three
patients died and causes of death were TRM in one patient
with infection and disease progression in two patients. In
earlier reports, myeloablative regimens were associated
with high early mortality rate, because of acute graft versus
host disease (aGVHD) and infection. In our report, 8 patients
developed grade 2-4 aGVHD (grade 2: 5, grade 3: 3, grade4:
0), but none of them died. Although number of patients is
small, allo-SCT with Flu+Mel+TBI is a tolerable and effective
treatment option for relapsed and refractory MM even with
unrelated donors.259
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Background: Mogamulizumab (anti-CCR4 monoclonal
antibody; MOG) is effective as a treatment for adult T-cell
leukemia/lymphoma (ATLL), but the inﬂuence of MOG
administration before allogeneic hematopoietic cell trans-
plantation (allo-HCT) on transplant outcomes is not clear.
We compared transplant outcomes in patients who
received MOG before allo-HCT with outcomes in those who
did not.
Methods: This study included 88 patients with ATLL who
underwent their ﬁrst allo-HCT between January 2001 and July
2014 at the National Cancer Center Hospital. Three patients
who received cord blood transplantation were excluded.
Results: MOG was used in 11 patients before allo-HCT. The
median time from the last MOG administration to allo-HCT
was 46 days (range, 17-198 days), and the median number
of administration was 5 times (range, 1-8 times). The me-
dian follow-up period among survivors was 1505 days after
HCT (range, 100-4393 days) in all patients, and the MOG
group had a shorter follow-up period (median 249 days,
range 101-284 days). More patients received tacrolimus-
based GVHD prophylaxis in MOG group than in non-MOG
group (n¼10 (91%) vs. n¼42 (55%), P¼0.024). There was no
signiﬁcant difference in other patient- and transplant-
related characteristics. The incidences of grade II-IV and
grade III-IV acute GVHD were 82% and 36%, respectively, inMOG group and 46% and 17%, respectively, in non-MOG
group. The incidence of grade II-IV acute GVHD in MOG
group was signiﬁcantly higher than that in non-MOG group
(P¼0.003). The cumulative incidence rate of non-relapse
mortality (NRM) and the overall survival (OS) rate at 6
months after allo-HCT were 58.2% and 31.8%, respectively, in
MOG group and 13.1% and 76.5%, respectively, in non-MOG
group. Patients in MOG group had signiﬁcantly worse out-
comes than those in non-MOG group (NRM, P¼0.001; OS,
P¼0.006). In MOG group, main causes of NRM included
infection after acute GVHD (n¼3) and multiple organ failure
(n¼2). In multivariate analyses, MOG administration before
HCT was a risk factor for grade II-IV acute GVHD (HR 3.57,
95%CI 1.62-7.78, P¼0.002) and NRM (HR 4.58, 95%CI 1.78-
11.82, P¼0.002).
Conclusion: Despite the small sample size and short obser-
vation period, our data suggested that the administration of
MOG before allo-HCT could increase risks of acute GVHD and
NRM. Appropriate management of acute GVHD including
prophylaxis and treatment should be investigated for ATLL
patients who received MOG before allo-HCT.260
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Hematopoietic stem cell transplantation (HSCT) is an
effective treatment for patients with refractory lymphomas.
Nucleoside analogues (NA) and DNA alkylating agents are
efﬁcacious in treating hematologic malignancies. To design
an efﬁcient, safe and more economical pre-transplant
conditioning regimen for lymphoma patients, we investi-
gated the cytotoxicity of cladribine (Clad), gemcitabine
(Gem), busulfan (Bu) and the histone deacetylase inhibitor
suberoylanilide hydroxamic acid, SAHA, as single agents, or
in combination, in the lymphoma cell lines J45.01 and
U937. [Clad+Gem+Bu] combinations synergistically inhibi-
ted the proliferation of both cell lines to 40-60% relative to
the control. Addition of SAHA to this combination increased
the inhibition to 55-70%. Investigation of the underlying
mechanisms of their synergism indicated that exposure of
lymphoma cells to [Clad+Gem+Bu] combination resulted in
DNA damage, activation of the ATM-CHK2 pathway, histone
modiﬁcations, decrease in the level of anti-apoptotic pro-
teins, and decrease in mitochondrial membrane potential
which caused leakage of apoptosis-inducing factors such
as cytochrome c and Smac/Diablo into the cytosol. These
cytocidal effects were greatly enhanced by SAHA. Pre-
treatment of J45.01 cells with a pan-caspase inhibitor,
Z-VAD-FMK, prior to exposure to the [Clad+Gem+Bu+SAHA]
combination blocked the activation of caspases, which
alleviated DNA damage and apoptosis, as shown by de-
creased phosphorylation of histone 2AX and cleavage of
PARP-1. Exposure of J45.01 cells to SAHA 4 hours prior to
the addition of the [Clad+Gem+Bu] combination resulted in
58% inhibition of proliferation relative to control, while
continuous exposure to [Clad+Gem+Bu] combination alone
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addition of [Clad+Gem+Bu] resulted in 40%, and 46% inhi-
bition, respectively (P ¼ 0.005). These results underscore
the importance of optimizing the sequence of drug expo-
sure. Our results provide a basis for using [Clad+Gem+Bu]
as a pre-transplant conditioning regimen for lymphoma
patients undergoing HSCT, and further addition of an
epigenetic modiﬁer, such as SAHA, may play a role as a
sensitizer to optimize the efﬁcacy of the chemotherapy
regimen.261
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Introduction: Studies suggest that the clonogenic cell in
Multiple Myeloma (MM) is a post-germinal center B-cell
expressing CD20, which makes it a potential target for
antibody therapy. 90Y-Zevalin (ibritumomab tiuxetan)
combines an anti-CD20 antibody with the radioisotope
yttrium-90, which has the potential to kill not only a tar-
geted CD20+ cell, but also neighboring plasma cells which
may not express CD20. This phase II trial evaluated the
safety and efﬁcacy of 90-Zevalin given prior to planned high
dose chemotherapy (melphalan 200mg/m2) and ASCT to
patients with incomplete response to prior chemotherapy
for MM.
Methods: Patients received a cold dose of rituximab
250mg/m2 followed by single dose of 0.4mCi/kg 90Y-Zevalin
(max 32mCi) at least 4weeks following last chemotherapy for
MM, corresponding to day -14 prior to ASCT. 111In-Zevalin
was given one week prior for imaging to conﬁrm expected
biodistribution. At least 14 days separated the outpatient
administration of 90Y-Zevalin and reinfusion of autologous
stem cells to allow for sufﬁcient 90Y decay. Response was
assessed andmelphalan administered on day -2 prior to ASCT
and again 90 days after ASCT. This non-randomized study
employed a Simon two-stage, minmax design. All patients
who received the therapeutic dose of 90Y-Zevalin were
included in theanalysis. Responsewas scoredaccording to the
criteria of Blade J, et al. (1998)
Results: Six patients received 90Y-Zevalin followed by
melphalan and ASCT (5 were male, age range 53-68, 2 were
second transplants). Median time to engraftment was 12
days (range 8-21). Four patients had measurable disease at
entry and were strictly evaluable for response. One patient
achieved partial response (PR) after 90Y-Zevalin and very
good PR after ASCT. Two patients achieved stable disease
(SD) after 90Y-Zevalin; and PR and complete response
respectively after ASCT. The fourth patient had progressive
disease (PD) after 90Y-Zevalin and SD after ASCT. A seventh
patient received 90Y-Zevalin with delayed ASCT in an initial
iteration of the protocol, with PD documented at >10 weeks.
Seven patients were evaluable for toxicity. There was no
infusion related toxicity. Four patients had peri-transplant
bacterial infections: line associated septic thrombosis,
bacteremia without source x 2, and peri-rectal abscessassociated with delayed engraftment prompting infusion of
back-up stem cells on day +19 and granulocytes.
Conclusion: Although the pre-speciﬁed response threshold
was reached in stage I; the modest response rate associated
with the high expense of radioimmunotherapy and concern
for a possible increase in peri-ASCT bacterial infections limits
enthusiasm for further study.
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Second autologous stem cell transplant (ASCT) is a treatment
option for multiple myeloma (MM) patients (pts) who have
disease progression after ﬁrst ASCT. Outcomes of second
ASCT in pts with renal dysfunction (RD) have not been
described.
We identiﬁed 18 pts at our institution who underwent a
second ASCT for relapsed MM and had evidence of RD
(creatinine clearance  60ml/min/1.73m2). Pts who under-
went a planned tandem transplant were excluded from this
analysis. Patient characteristics are shown in Table 1. Ten pts
received one chemotherapy (CT) regimen while nine pts
received two or more CT regimens between ﬁrst and second
ASCT. The CT regimens used between ﬁrst and second
transplant included Imid based (n¼6), proteosome inhibitor
based (n¼3) and combination of both (n¼9). Approximately
half of the pts had progressive disease at the time of second
ASCT. Median creatinine clearance at the time of second
ASCT was 43.5 ml/min/1.73m2. One pt was dialysis depen-
dent. All pts received G-CSF 5mg/Kg from day + 6 till ANC was
1500/ mL.
Median follow up post second ASCT was 17.1 months
(range, 2.4-100). One pt died at day 74 due to multi organ
failure. Of 17 evaluable pts at day 100, twelve had an up-
grade from the disease response category achieved with
the last regimen used prior to second ASCT while ﬁve pts
had stable disease response. Three pts received mainte-
nance therapy after the second ASCT with bortezomib(n¼2)
and lenalidomide (n¼1). Figure 1 shows the overall survival
(OS) after second ASCT and Figure 2 shows the relapse free
survival (RFS) from ﬁrst and second ASCT. After the second
ASCT, the median OS was 27 months while the median RFS
was 22.2 months (median RFS after ﬁrst ASCT was 24
months).
The transplant related mortality of these pts was not higher
than expected and the median RFS of about 2 years makes
the option of second ASCT in this group of patients a valuable
treatment modality and is comparable to reported outcomes
after second ASCT. In addition, the RFS after second ASCTwas
